Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity

Oncoimmunology. 2014 Aug 3;3(8):e954460. doi: 10.4161/21624011.2014.954460. eCollection 2014.


Cytotoxic drugs capable of killing cancer cells in conjunction with targeted conversion of tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs) are highly complementary therapeutic routes to boost antitumor immunity. Our data suggest that the microtubule-depolymerizing compounds Dolastatin 10 and Ansamitocin P3 may serve as prototypes for a class of agents that display this binary mode of action.

Keywords: DC maturation; T cells; anti-tumor immunity; antibody-drug conjugates; cancer; immune response; microtubule-depolymerizing chemotherapy.